<DOC>
	<DOCNO>NCT01529437</DOCNO>
	<brief_summary>This study child adult interested new therapy allergy dust mite timothy grass . The new therapy call sublingual immunotherapy investigator test safe well tolerate .</brief_summary>
	<brief_title>Sublingual Immunotherapy Studies Grass Dust Mite Allergies</brief_title>
	<detailed_description>This phase I , single-center , randomize , placebo-controlled study sublingual immunotherapy ( SLIT ) pediatric adult subject house dust mite ( HDM ) timothy grass ( TG ) allergy . We evaluate whether Dermatophagoides farinae ( DF ) and/or TG allergen SLIT safe child adult . We also determine whether treatment DF and/or TG SLIT reduce severity allergic symptom ( allergic rhinitis , allergic conjunctivitis ) enhance resolution . The study also evaluate whether SLIT provide robust durability response terminate . The dosing-phase study last 12 month . In addition , follow period 2 year occur . Approximately 10 subject placebo , 20 active treatment .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>SUBJECT INCLUSION CRITERIA : 1 . Pediatric adult timothy grass Dermatophagoides farinaesensitive subject allergic rhinoconjunctivitis without asthma perennially grass pollen season . 2 . Subjects must 5 year age old . 3 . Sensitivity relevant allergen document positive skin prick test result ( see Appendix E detail ) . 4 . All female subject childbearing potential require provide urine sample pregnancy test must negative one week allow participate study . 5 . Subjects must plan remain study area trial . 6 . Subjects and/or parent must train proper use EpiPen allow enroll study . 7 . Subjects and/or parent must mentally physically capable selfadministering oral drug . SUBJECT EXCLUSION CRITERIA : No absolute contraindication allergen skin test and/or sublingual immunotherapy know . However , risk serious systemic anaphylactic reaction pollen potent allergenic extract suggest number preexist condition consider relative contraindication . Among condition acute infection , autoimmune disease , severe cardiac disease , treatment betaadrenergic antagonistic drug ( betablockers ) . 1 . Subjects history unexplained anaphylaxis within 2 year history multiple ( â‰¥2 ) episodes anaphylaxis past year , frequent allergic nonallergic urticaria , history consistent poorly control persistent asthma . Anaphylaxis must medically diagnose . 2 . Subjects unstable angina , significant arrhythmia , uncontrolled hypertension , chronic sinusitis , chronic immunological disease mind investigator might interfere evaluation administration test drug pose additional risk subject e.g . gastrointestinal gastroesophageal disease , chronic infection , scleroderma , hepatic gallbladder disease , chronic nonallergic pulmonary disease . 3 . Subject FEV1 PEF le 80 % predict ( moderate persistent asthma ) without controller medication . 4 . Subjects receive experimental drug last 30 day prior admission study plan use experimental drug study . 5 . Subjects receive timothy grass dust mite allergen immunotherapy within 3 year prior admission study . 6 . Subjects current user oral , intramuscular , intravenous corticosteroid , tricyclic antidepressant , take betablocker ( oral topical ) . 7 . Subjects routinely use medication could induce adverse gastrointestinal reaction study . 8 . Subjects refuse sign EpiPen Training Form ( see Appendix F ) . 9 . Pregnant breast feeding female . 10 . Subjects symptoms dose level 1 2 Preliminary Dosing Visit ( see , ) . 11 . Subjects significant pet allergy significant exposure home work .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>allergy</keyword>
	<keyword>immunology</keyword>
	<keyword>immune tolerance</keyword>
	<keyword>immunotherapy</keyword>
</DOC>